Biogen Stock Outlook: Is Wall Street Bullish or Bearish?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 24 2025
0mins
Source: NASDAQ.COM
Biogen's Performance: Biogen Inc. has seen a significant decline in its stock, down 36.4% over the past year, underperforming compared to the S&P 500 Index and the iShares Neuroscience and Healthcare ETF, despite reporting a 3% revenue increase in Q4 that surpassed analyst expectations.
Analyst Ratings and Outlook: The consensus among analysts is a "Moderate Buy" for Biogen, with a lowered price target of $135 from Piper Sandler, while the mean price target suggests a potential upside of 41.4%, indicating cautious optimism amid a conservative earnings forecast for 2025.
Analyst Views on IBRN
Wall Street analysts forecast IBRN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IBRN is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 32.790
Low
Averages
High
Current: 32.790
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
